Author: Christoph Nitsche

  • Peptide-Bismuth Bicycles

    Congratulations to Saan from our group who published a paper in Angewandte Chemie. In this study, we introduce peptide-bismuth bicycles as a fundamentally new class of constrained peptides with superior stability and bioactivity. Voss, S., Rademann, J., Nitsche, C.,* Peptide-Bismuth Bicycles: In Situ Access to Stable Constrained Peptides with Superior Bioactivity, Angew. Chem. Int. Ed. 2021, 10.1002/anie.202113857.

  • SARS-CoV-2 main protease

    This week we published two papers on peptides targeting the SARS-CoV-2 main protease. Amazing collaborations within ANU and with scientists at the University of Sydney. Great contribution from Sven from our lab who worked tirelessly on this project over the last 18 months. Publication in Bioorganic and Medicinal Chemistry Letters Preprint on bioRxiv

  • Targeting the West Nile Virus Protease

    Congratulations to Saan for an excellent perspective about the protease of West Nile virus published in the Emerging Investigator issue of RSC Medicinal Chemistry.

  • CINA Conjugation

    Congratulations to everyone who contributed to our latest publication in ACS Medicinal Chemistry Letters introducing CINA conjugation as a new powerful tool for peptide ligation and macrocyclisation. This was a great collaboration with Nitin Patil from Monash University as well as Dahai Luo’s lab in Singapore and the Rademann lab in Berlin.

  • Biocompatible peptide stapling

    Congratulations to Richard who just published a new biocompatible strategy for peptide stapling in Chemical Science. The approach can be used to constrain peptides directly in biochemical assays and thus identify promising ligands for drug discovery.

  • The SARS-CoV-2 main protease as drug target

    Congratulations to Sven, who published an article in Bioorganic & Medicinal Chemistry Letters about the prospects of main protease inhibitors as antiviral agents to combat COVID-19. Our article is open access and available to everyone.

  • Small molecules inhibit flavivirus proteases in the active site

    Check out our latest article published in ACS Medicinal Chemistry Letters in close collaboration with the Wolber and Rademann laboratories in Berlin. For the first time, we demonstrate that small molecules can target the active sites of Zika, West Nile and dengue virus proteases with extraordinarily high affinities.

  • Inhibitors of the Zika virus protease NS2B-NS3

    Congratulations to Saan, who published an article in Bioorganic & Medicinal Chemistry Letters about the latest prospects of protease inhibitors as antiviral agents to combat infections with the Zika virus. Our article is featured on the cover of the latest issue.

  • Biocompatible Peptide Macrocyclisation Generates Stable Protease Inhibitors

    Check out our latest research article published in Organic Letters about a novel strategy to spontaneously cyclise peptides under physiological conditions. A substrate peptide of the Zika virus protease cyclised in this way produced an inhibitor of remarkable affinity and stability.

  • Proteases from dengue, West Nile and Zika viruses as drug targets

    Check out our latest review about the potential of protease inhibitors to combat diseases associated with dengue, West Nile and Zika virus infections published in Biophysical Reviews.